Key result
Rosuvastatin/ezetimibe combination therapy reduced serum sEGFR levels in type 2 diabetes patients with hypercholesterolemia.
Why the study?
Soluble epidermal growth factor receptor (sEGFR) levels are elevated in type 2 diabetes mellitus, but how cholesterol-lowering treatment affects sEGFR levels remains unknown.
Does rosuvastatin/ezetimibe combination therapy reduce sEGFR levels compared to rosuvastatin monotherapy in patients with type 2 diabetes and hypercholesterolemia?
Observational (n=115)
Does rosuvastatin/ezetimibe combination therapy reduce sEGFR levels compared to rosuvastatin monotherapy in patients with type 2 diabetes and hypercholesterolemia?
Cholesterol-lowering treatment with rosuvastatin alone or in combination with ezetimibe significantly reduces serum sEGFR levels in patients with type 2 diabetes and hypercholesterolemia, suggesting a potential role for sEGFR as a biomarker for lipid-lowering response.
Answers are grounded in this paper and cite their sources.
Does not support changing lipid therapy in type 2 diabetes; leaves open sEGFR as response biomarker pending prospective trials.
Soluble epidermal growth factor receptor (sEGFR) levels are elevated in patients with type 2 diabetes mellitus (T2DM) and positively correlate with blood glucose and cholesterol levels. However, how cholesterol-lowering treatment in patients with T2DM affects the sEGFR level is unknown. Therefore, we investigated the change of serum sEGFR after cholesterol-lowering treatment in type 2 diabetic patients with hypercholesterolemia. This study is a non-randomized, prospective observational study. A total of 115 patients were treated in either the rosuvastatin monotherapy group (R group, 5 mg/day, n = 59) or the rosuvastatin/ezetimibe combination therapy group (RE group, 5 mg/10 mg/day, n = 56) for 12 weeks. We measured serum levels of lipids and sEGFR using an ELISA kit before and after 12 weeks of treatment in each group. The low-density lipoprotein cholesterol (LDL-C) level was significantly reduced (from 130.27 ± 27.09 to 76.24 ± 26.82 mg/dL; P < .001) after 12 weeks of treatment and more so in the RE group than in the R group (from 131.68 ± 28.72 to 87.13 ± 27.04 mg/dL, P < .001 in the R group; from 128.78 ± 25.58 to 64.75 ± 21.52 mg/dL, P < .001 in the RE group; R vs RE group, P < .001). The sEGFR level was significantly decreased after 12 weeks of treatment (from 50.34 ± 13.31 to 45.75 ± 11.54 ng/mL; P = .007). The RE group only showed a significant reduction in the sEGFR level after treatment (from 50.94 ± 12.10 to 44.80 ± 11.36 ng/mL; P = .007). Moreover, the sEGFR level was significantly reduced only when the LDL-C level was significantly reduced (from 50.46 ± 10.66 to 46.24 ± 11.86 ng/mL; P = .043). The serum sEGFR level was significantly reduced by cholesterol-lowering treatment with rosuvastatin alone or rosuvastatin/ezetimibe. We suggested that sEGFR may play a significant role in insulin resistance (IR) and inflammation, which are central pathophysiological mechanisms. We confirmed the possibility of using sEGFR as a biomarker to predict a good response to lipid-lowering treatment in type 2 diabetes patients with hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted an observational in type 2 diabetes with hypercholesterolemia (n=115). rosuvastatin/ezetimibe combination therapy vs. rosuvastatin monotherapy was evaluated on change in serum sEGFR level (p=.007). Rosuvastatin/ezetimibe combination therapy reduced serum sEGFR levels in type 2 diabetes patients with hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: